HBM Healthcare Investments AG / Key word(s): Half-year results
03-Oct-2022 / 17:47 CET/CEST
The net asset value per share (NAV) as of September 30, 2022 amounts to CHF 270.92 and is therefore 1.7% lower than at the beginning of the current financial year 2022/23. In comparison, the MSCI World Health Care Sector Index fell 7.7% and the Nasdaq Biotechnology Index fell 3.1%.
Based on the published NAV, HBM Healthcare Investments expects a loss of CHF 34 million for the first half of the year. The result was strongly influenced by the listed investment in Cathay Biotech. The company’s market capitalization on the Shanghai Stock Exchange fell by just over a fifth. Cathay Biotech, a leader in the growing synthetic biology market, is debt-free, profitable, and shows steadily increasing sales and profits. The other private and listed investments in the portfolio have generally evolved positively in value. It is also thanks to the four acquisitions of Sierra Oncology, Biohaven, Turning Point Therapeutics and more recently ChemoCentryx from the portfolio of listed companies.
The figures presented here are the preliminary result based on the current status of the closing process. The final result will be published with the half-year report on October 21, 2022.
End of privileged information
|Company:||HBM Healthcare Investments SA|
|Federal square 1|
|Listed:||SIX Swiss Stock Exchange|
|EQS News ID:||1455715|
|End of announcement||EQS News Service|
1455715 03-Oct-2022 CET/CEST